Long-term outcomes of patients treated with 19-28z CAR EBV-VSTs. (A) OS of patients with B-ALL vs NHL. (B) OS of patients with CAR EBV-VST products from their transplant donor vs a third-party donor. (C) EFS of patients with B-ALL vs NHL. (D) EFS of patients with CAR EBV-VST products from their transplant donor vs a third-party donor. Note: patients with no initial response to treatment are included with event time of 0. NHL, non-Hodgkin lymphoma.